ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1838

Antibodies Against Bacterial Products Curli/DNA Are Found in Lupus Patients and Are Associated with Disease Flares

Ryan Pachucki1, Sarah Tursi2, Chelsea Corradetti1, Lynne Kohler3, Stefania Gallucci2, Cagla Tukel2 and Roberto Caricchio1, 1Medicine Rheumatology, Lewis Katz School of Medicine, Philadelphia, PA, 2Microbiology and Immunology, Lewis Katz School of Medicine, Philadelphia, PA, 3Lewis Katz School of Medicine, Philadelphia, PA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: autoantibodies and bacterial infections, Lupus

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Bacterial infections are a major contributor to morbidity and mortality in SLE, a known trigger of flares and they are often difficult to distinguish from lupus flares as a definitive biomarker is still lacking. Urinary tract infections (UTIs) such as those due to uropathogenic E. coli (UPEC), are characterized by the generation of a unique form of amyloid called curli. We have previously demonstrated that curli amyloid can induce or accelerate disease in mouse models of SLE. Curli can strengthen the structure of biofilms and integrate extracellular DNA, which in turn can be both adjuvant and a self-antigen in lupus patients. Curli can elicit a humoral response against themselves. Based on our previous results, we hypothesize that SLE patients can generate anti-Curli/DNA antibodies and that they correlate with flares

Methods: We investigated 34 lupus patients who met at least 4 SLICC criteria, 29 women and 5 men. 17 sex matched healthy controls were used. We developed a novel ELISA to detect anti-curli antibodies by using the curli/DNA complex as antigen. We tested IgG and IgA subclasses. We also performed competitive ELISAs to determine if curli/DNA antibodies cross reacted with classic lupus autoantibodies. Finally, we correlated the levels of anti-curli/DNA antibodies with several clinical parameters including anti-dsDNA antibodies, bacteriuria and disease flares (SLEDAI). Flares were calculated as an increase of at least 3 points in the SLEDAI from the prior visit.

Results: We found that Lupus patients and healthy controls generated anti-curli antibodies of both IgG and IgA subclasses. We also found that anti-curli antibodies recognized human chromatin but not dsDNA. Interestingly, female lupus patients had significant higher levels of anti-curli antibodies than female controls and males with lupus (p=0.047 and p=0.026 respectively). Remarkably, higher levels of anti-curli antibodies significantly correlated with the levels of anti-dsDNA antibodies (p=0.029), persistent bacteriuria (p=0.035) and lupus flares (p=0.024).

Conclusion: Taken together these results demonstrate that both healthy controls and lupus patients are exposed to curli-forming bacteria and generate systemic and mucosal immune responses (IgG and IgA subclasses) against curli. Moreover, women with SLE have much higher levels of anti-curli antibodies than men possibly due to higher rate of urinary tract infection, especially by E. coli. Since many female patients had persistent bacteriuria, bacterial colonization could be a significant pathogenic mechanism in lupus. Finally, the levels of anti-curli antibodies in lupus patients are a promising biomarker of flares.


Disclosure: R. Pachucki, None; S. Tursi, None; C. Corradetti, None; L. Kohler, None; S. Gallucci, None; C. Tukel, None; R. Caricchio, None.

To cite this abstract in AMA style:

Pachucki R, Tursi S, Corradetti C, Kohler L, Gallucci S, Tukel C, Caricchio R. Antibodies Against Bacterial Products Curli/DNA Are Found in Lupus Patients and Are Associated with Disease Flares [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/antibodies-against-bacterial-products-curlidna-are-found-in-lupus-patients-and-are-associated-with-disease-flares/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibodies-against-bacterial-products-curlidna-are-found-in-lupus-patients-and-are-associated-with-disease-flares/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology